Acuren price target lowered to $11.50 from $12 at UBS

UBS lowered the firm’s price target on Acuren (TIC) to $11.50 from $12 and keeps a Neutral rating on the shares. Acuren announced an agreement to acquire NV5 (NVEE), which has good strategic appeal, though Q1 EBITDA was softer amid stronger revenue, the analyst tells investors in a research note.